Prolactin activates erα in the absence of ligand in female mammary development and carcinogenesis in vivo

Endocrinology

Volumn 154, Issue 12, 2013, Pages 4483-4492

  O'Leary, Kathleen A ^a   Jallow, Fatou ^a   Rugowski, Debra E ^a   Sullivan, Ruth ^a   Sinkevicius, Kerstin W ^b,c   Greene, Geoffrey L ^b   Schuler, Linda A ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; PROLACTIN; STAT5B PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA; ESTRADIOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST DEVELOPMENT; BREAST EPITHELIUM; CONTROLLED STUDY; ESTROGEN ACTIVITY; FEMALE; GENE EXPRESSION; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; AGING; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOGENESIS; EXPERIMENTAL MAMMARY NEOPLASM; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MUTATION; TRANSGENIC MOUSE; UDDER;

AGING; ANIMALS; CARCINOGENESIS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; MUTATION; PROLACTIN; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 84888229403     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1533     Document Type: Article

References (73)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-1717.
2. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9:631-643.
3. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Ann Rev Med. 2011;62:233-247.
4. Roop RP, Ma CX. Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies. Future Oncol. 2012;8:273-292.
5. Tworoger SS, Hankinson SE. Prolactin and breast cancer etiology: an epidemiologic perspective. J Mammary Gland Biol Neoplasia. 2008;13:41-53.
6. Dowsett M, McGarrick GE, Harris AL, Coombes RC, Smith IE, Jeffcoate SL. Prognostic significance of serum prolactin levels in advanced breast cancer. Br J Cancer. 1983;47:763-769.
7. Bhatavdekar JM, Patel DD, Karelia NH, et al. Can plasma prolactin predict tamoxifen resistance in patients with advanced breast cancer? Eur J Surg Oncol. 1994;20:118-121.
8. Barni S, Lissoni P, Meregalli S, et al. Clinical efficacy of the aromatase inhibitor anastrozole in relation to prolactin secretion in heavily pretreated metastatic breast cancer. Tumori. 1998;84:45-47.
9. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9:166-180
10. Holtkamp W, Nagel GA, Wander HE, Rauschecker HF, von Heyden D. Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer. Int J Cancer. 1984;34:323-328.
11. Wu ZS, Yang K, Wan Y, et al. Tumor expression of human growth hormone and human prolactin predict a worse survival outcome in patients with mammary or endometrial carcinoma. J Clin Endocrinol Metab. 2011;96:E1619-1629.
12. Frontini L, Lissoni P, Vaghi M, et al. Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pretreated metastatic breast cancer. Anticancer Res. 2004;24:4223-4226.
13. Bhatavdekar JM, Patel DD, Shah NG, et al. Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis. Ann Surg Oncol. 2000;7:305-311.
14. Tworoger SS, Eliassen AH, Zhang X, et al. A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res. 2013;73:4810-4819.
15. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA. Prolactin induces ERα-positive and ERα-negative mammary cancer in transgenic mice. Oncogene. 2003;22:4664-4674.
16. Arendt LM, Schuler LA. Transgenic models to study actions of prolactin in mammary neoplasia. J Mammary Gland Biol Neoplasia. 2008;13:29-40.
17. Zinger M, McFarland M, Ben-Jonathan N. Prolactin expression and secretion by human breast glandular and adipose tissue explants. J Clin Endocrinol Metab. 2003;88:689-696.
18. McHale K, Tomaszewski JE, Puthiyaveettil R, Livolsi VA, Clevenger CV. Altered expression of prolactin receptor-associated signaling proteins in human breast carcinoma. Mod Pathol. 2008;21:565-571.
19. Arendt LM, Rugowski DE, Grafwallner-Huseth TA, Garcia-Barchino MJ, Rui H, Schuler LA. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. Breast Cancer Res. 2011;13:R11-25.
20. Arendt LM, Evans LC, Rugowski DE, Garcia-Barchino MJ, Rui H, Schuler LA. Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes. J Endocrinol. 2009;203:99-110.
21. Weigel NL, Moore NL. Steroid receptor phosphorylation: a key modulator of multiple receptor functions. Mol Endocrinol. 2007; 21:2311-2319.
22. Murphy LC, Seekallu SV, Watson PH. Clinical significance of estrogen receptor phosphorylation. Endocr Relat Cancer. 2011;18:R1-R14.
23. Le Romancer M, Poulard C, Cohen P, Sentis S, Renoir JM, Corbo L. Cracking the estrogen receptor's posttranslational code in breast tumors. Endocr Rev. 2011;32:597-622.
24. de Leeuw R, Neefjes J, Michalides R. 2011 A role for estrogen receptor phosphorylation in the resistance to tamoxifen. Int J Breast Cancer. 2011;232435.
25. Arendt LM, Schuler LA. Prolactin drives estrogen receptor-α- dependent ductal expansion and synergizes with transforming growth factor-α to induce mammary tumors in males. Am J Pathol. 2008;172:194-202.
26. Arendt LM, Grafwallner-Huseth TL, Schuler LA. Prolactin-growth factor crosstalk reduces mammary estrogen responsiveness despite elevated ERα expression. Am J Pathol. 2009;174:1065-1074.
27. González L, Zambrano A, Lazaro-Trueba I, et al. Activation of the unliganded estrogen receptor by prolactin in breast cancer cells. Oncogene. 2009;28:1298-1308.
28. Arendt LM, Rose-Hellekant TA, Sandgren EP, Schuler LA. Prolactin potentiates transforming growth factor α induction of mammary neoplasia in transgenic mice. Am J Pathol. 2006;168:1365-1374.
29. Huang Y, Li X, Jiang J, Frank SJ. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells. Oncogene. 2006;25:7565-7576.
30. Carver KC, Schuler LA. Prolactin does not require insulin-like growth factor intermediates, but synergizes with insulin-like growth factor I in human breast cancer cells. Mol Cancer Res. 2008;6:634-643.
31. Carver KC, Piazza TM, Schuler LA. Prolactin enhances insulin-like growth factor I receptor phosphorylation by decreasing its association with the tyrosine phosphatase SHP-2 in MCF-7 breast cancer cells. J Biol Chem. 2010;285:8003-8012.
32. Yamauchi T, Yamauchi N, Ueki K, et al. Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer. J Biol Chem. 2000;275:33937-33944.
33. Sakamoto K, Triplett AA, Schuler LA, Wagner KU. Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer. Oncogene. 2010;29:5359-5369.
34. Stern DF. ErbBs in mammary development. Exp Cell Res. 2003;284:89-98.
35. Eccles SA. The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Int J Dev Biol. 2011;55:685-696.
36. Sinkevicius KW, Burdette JE, Woloszyn K, et al. An estrogen receptor-α knock-in mutation provides evidence of ligand-independent signaling and allows modulation of ligand-induced pathways in vivo. Endocrinology. 2008;149:2970-2979.
37. Medina D, Kittrell FS, Hill J, Shepard A, Thordarson G, Brown P. Tamoxifen inhibition of estrogen receptor-α-negative mouse mammary tumorigenesis. Cancer Res. 2005;65:3493-3496.
38. Vyhlidal C, Samudio I, Kladde MP, Safe S. Transcriptional activation of transforming growth factor α by estradiol: requirement for both a GC-rich site and an estrogen response element half-site. J Mol Endocrinol. 2000;24:329-338.
39. Rose-Hellekant TA, Schroeder MD, Brockman JL, et al. Estrogen receptor-positive mammary tumorigenesis in TGFα transgenic mice progresses with progesterone receptor loss. Oncogene. 2007;26:5238-5246.
40. Mallepell S, Krust A, Chambon P, Brisken C. Paracrine signaling through the epithelial estrogen receptor α is required for proliferation and morphogenesis in the mammary gland. Proc Natl Acad Sci USA. 2006;103:2196-2201.
41. Feng Y, Manka D, Wagner KU, Khan SA. Estrogen receptor-α expression in the mammary epithelium is required for ductal and alveolar morphogenesis in mice. Proc Natl Acad Sci USA. 2007;104:14718-14723.
42. Van Keymeulen A, Rocha AS, Ousset M, et al. Distinct stem cells contribute to mammary gland development and maintenance. Nature. 2011;479:189-193.
43. Deroo BJ, Hewitt SC, Collins JB, Grissom SF, Hamilton KJ, Korach KS. Profile of estrogen-responsive genes in an estrogen-specific mammary gland outgrowth model. Mol Reprod Dev. 2009;76:733-750.
44. McBryan J, Howlin J, Kenny PA, Shioda T, Martin F. ERα-CITED1 co-regulated genes expressed during pubertal mammary gland development: implications for breast cancer prognosis. Oncogene. 2007;26:6406-6419.
45. Sinkevicius KW, Woloszyn K, LaineM,et al. Characterization of the ovarian and reproductive abnormalities in prepubertal and adult estrogen non-responsive estrogen receptor α knock-in (ENERKI) mice. Steroids. 2009;74:913-919.
46. Ellison-Zelski SJ, Solodin NM, Alarid ET. Repression of ESR1 through actions of estrogen receptor α and Sin3A at the proximal promoter. Mol Cell Biol. 2009;29:4949-4958.
47. Kraus WL, Montano MM, Katzenellenbogen BS. Identification of multiple, widely spaced estrogen-responsive regions in the rat progesterone receptor gene. Mol Endocrinol. 1994;8:952-969.
48. Hennighausen L, Robinson GW, Wagner KU, Liu W. Prolactin signaling in mammary gland development. J Biol Chem. 1997;272:7567-7569.
49. Peck AR, Witkiewicz AK, Liu C, et al. Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes. Breast Cancer Res. 2012;14:R130.
50. Furth PA, Nakles RE, Millman S, Diaz-Cruz ES, CabreraMC. Signal transducer and activator of transcription 5 as a key signaling pathway in normal mammary gland developmental biology and breast cancer. Breast Cancer Res. 2011;13:220.
51. Koptyra M, Gupta S, Talati P, Nevalainen MT. Signal transducer and activator of transcription 5a/b: biomarker and therapeutic target in prostate and breast cancer. Int J Biochem Cell Biol. 2011;43:1417-1421.
52. Frasor J, Gibori G. Prolactin regulation of estrogen receptor expression. Trends Endocr Metab. 2003;14:118-123.
53. Gutzman JH, Miller KK, Schuler LA. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor α and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells. J Steroid Biochem Mol Biol. 2004;88:69-77.
54. Dong J, Tsai-Morris CH, Dufau ML. A novel estradiol/estrogen receptor α-dependent transcriptional mechanism controls expression of the human prolactin receptor. J Biol Chem. 2006;281:18825-18836.
55. Gutzman JH, Nikolai SE, Rugowski DE, Watters JJ, Schuler LA. Prolactin and estrogen enhance the activity of activating protein 1 in breast cancer cells: role of extracellularly regulated kinase 1/2-mediated signals to c-fos. Mol Endocrinol. 2005;19:1765-1778.
56. Shen Q, Zhang Y, Uray IP, et al. The AP-1 transcription factor regulates postnatal mammary gland development. Dev Biol. 2006;295:589-603.
57. Damiano JS, Rendahl KG, Karim C, et al. Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer. Mol Cancer Ther. 2013;12:295-305.
58. Anderson WF, Matsuno R. Breast cancer heterogeneity: a mixture of at least two main types? J Natl Cancer Inst. 2006;98:948-951.
59. Stingl J. Estrogen and progesterone in normal mammary gland development and in cancer. Horm Cancer. 2011;2:85-90.
60. Stingl J, Eirew P, Ricketson I, et al. Purification and unique properties of mammary epithelial stem cells. Nature. 2006;439:993-997.
61. Cariati M, Naderi A, Brown JP, et al. α-6 Integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer. 2008;122:298-304.
62. Oh DS, Troester MA, Usary J, et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol. 2006;24:1656-1664.
63. Creighton CJ. The molecular profile of luminal B breast cancer. Biologics. 2012;6:289-297.
64. Huderson BP, Duplessis TT, Williams CC, et al. Stable inhibition of specific estrogen receptor α (ERα) phosphorylation confers increased growth, migration/invasion, and disruption of estradiol signaling in MCF-7 breast cancer cells. Endocrinology. 2012;153:4144-4159.
65. Calvo E, Luu-The V, Belleau P, Martel C, Labrie F. Specific transcriptional response of four blockers of estrogen receptors on estra-diol-modulated genes in the mouse mammary gland. Breast Cancer Res Treat. 2012;134:625-647.
66. Kazansky AV, Kabotyanski EB, Wyszomierski SL, Mancini MA, Rosen JM. Differential effects of prolactin and src/abl kinases on the nuclear translocation of STAT5B and STAT5A. J Biol Chem. 1999;274:22484-22492.
67. Silva CM, Shupnik M A. Integration of steroid and growth factor pathways in breast cancer: focus on signal transducers and activators of transcription and their potential role in resistance. Mol Endocrinol. 2007;21:1499-1512.
68. Carver KC, Arendt LM, Schuler LA. Complex prolactin crosstalk in breast cancer: new therapeutic implications. Mol Cell Endocrinol. 2009;307:1-7.
69. Darnell JE Jr. STATs and gene regulation. Science 1997;277:1630-1635.
70. Boerner JL, Gibson M A, Fox EM, et al. Estrogen negatively regulates epidermal growth factor (EGF)-mediated signal transducer and activator of transcription 5 signaling in human EGF family receptor-overexpressing breast cancer cells. Mol Endocrinol. 2005;19:2660-2670.
71. Riggins RB, Thomas KS, Ta HQ, et al. Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Res. 2006;66:7007-7015.
72. Tang JZ, Zuo ZH, Kong XJ, et al. Signal transducer and activator of transcription (STAT)-5A and STAT5B differentially regulate human mammary carcinoma cell behavior. Endocrinology. 2010;151:43-55.
73. Bernaciak TM, Zareno J, Parsons JT, Silva CM. A novel role for signal transducer and activator of transcription 5b (STAT5b) in beta1-integrin-mediated human breast cancer cell migration. Breast Cancer Res. 2009;11:R52.